These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 20103628

  • 1. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
    Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B.
    Cancer Res; 2010 Feb 01; 70(3):1204-14. PubMed ID: 20103628
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
    Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B.
    Mol Cancer; 2013 Nov 11; 12(1):134. PubMed ID: 24215614
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
    Breast Cancer Res; 2007 Nov 11; 9(4):R50. PubMed ID: 17686159
    [Abstract] [Full Text] [Related]

  • 6. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD.
    Cell Cycle; 2011 Sep 01; 10(17):2959-66. PubMed ID: 21862872
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
    Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M.
    J Natl Cancer Inst; 2001 Dec 19; 93(24):1852-7. PubMed ID: 11752009
    [Abstract] [Full Text] [Related]

  • 9. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
    Lu Y, Zi X, Pollak M.
    Int J Cancer; 2004 Jan 20; 108(3):334-41. PubMed ID: 14648698
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance.
    Dokmanovic M, Shen Y, Bonacci TM, Hirsch DS, Wu WJ.
    Mol Cancer Ther; 2011 Jun 20; 10(6):917-28. PubMed ID: 21487052
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 20; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.